S944
Clinical - Non-malignant & functional radiotherapy
ESTRO 2026
(range:5400 -14000). The median beam-on time (BOT) was 6 minutes (range: 4 min- 9 min 40 s). The PTV D98%, PTV near-maximum dose (Dnear max), and ITV Dnear-max values were 97.25% (range: 84.8-98.42), 30.2 Gy (28.8-33.61), and 31.1 Gy (30.1-34.28), respectively. In 50% of the treatment plans, PTV coverage was less than 98% due to proximity of critical OARs. R50 values was met the protocol. Dose constraints for certain cardiac organs and substructures were intentionally exceeded when clinically justified. All treatment plans were confirmed deliverable on patient-specific quality assurance (PSQA)(Table 1).
role in medical research.PMID:224122273. Short- course preop RT with delayed surgery in rectal cancer. PMID:180936744. Effective, efficient palliative RT for advanced HNC. PMID:39929114.5. Late GU toxicity following EBRT for prostate cancer in FLAME trial. PMID:349684706. Late GI toxicity following EBRT for prostate cancer in FLAME trial. PMID:342146147. Cancer incidence after localized therapy for prostate cancer. PMID:168783238. Prostatic irradiation is not associated with any measurable increase in risk of subsequent rectal cancer. PMID:16545920 Keywords: benign prostate hyperplasia, radiotherapy Digital Poster 1520 Stereotactic Arrhythmia Radioablation (STAR): Initial mono centric experience Francesca Romana Giglioli 1 , Veronica Richetto 1 , Elena Gallio 1 , Christian Fiandra 2 , Marzia Cerrato 3 , Ada Celislami 2 , Umberto Ricardi 2 , Mario Levis 2 1 Medical Physics Unit, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy. 2 Department of Oncology, University of Turin, Turin, Italy. 3 Radiation Oncology Unit, Department of Oncology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy Purpose/Objective: Stereotactic arrhythmia radioablation (STAR) has shown promising safety and efficacy for treating refractory ventricular tachycardia. STAR delivers a single 25 Gy fraction to the arrhythmogenic substrate using stereotactic body radiotherapy (SBRT). The objective of this study was to evaluate the feasibility and safety of implementing STAR on a linear accelerator (LINAC) platform. Material/Methods: Treatments were delivered on a Versa HD linear accelerator utilizing a 6 MV FFF beam. The internal target volume (ITV) approach was based on 4DCT. Planning typically used two coplanar left-sided beams, with an anterior non-coplanar beam added when required. A 4DCBCT was also acquired on the treatment unit. Prescriptions followed ICRU 91 guidelines: 25 Gy to cover 98% of the PTV with heterogeneous dose distribution. Thirty cardiac structures and substructures were contoured. Doses to the PTV, relevant extra-cardiac OARs, and cardiac substructures were analysed using descriptive statistics, monitor units (MUs) and R50 were also evaluated. R50 was defined as the ratio of the 50% prescription isodose cloud volume to the planning target volume, with reference values dependent on PTV size (EORTC-2387). Results: Ten patients were treated;90% of plans included non- coplanar beam. The median MUs delivered was 8300
Conclusion: STAR is a complex multidisciplinary treatment in which all the team (Radiation oncologists, medical physicists, and cardiologists) plays a crucial role. Their expertise is essential to ensure accuracy and safety, thereby significantly enhancing overall treatment effectiveness. Keywords: STAR, Cardiac ablation Hypo-fractionated radiotherapy to the stellate ganglia for ventricular arrhythmia (RADIO STAR) trial (ISRCTN 49861434) Ami Sabharwal 1,2 , Ben George 2 , Ebison Chinherende 2 , Maxwell Robinson 1 , Veni Enzhil 2 , Bleddyn Jones 3 , Fintan Sheerin 4,5 , Sukumar Prabakar 1 , Tom Whyntie 2 , James T Grist 6 , Benjamin Bussmann 6,7 , Neil Herring 6,7 1 Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 2 Oncology, GenesisCare, Oxford, United Kingdom. 3 Oncology, University of Oxford, Oxford, United Kingdom. 4 Radiology, Oxford University Hospitals NHS Mini-Oral 1546 Foundation Trust, Oxford, United Kingdom. 5 Radiology, GenesisCare, Oxford, United Kingdom. 6 Cardiology, University of Oxford, Oxford, United Kingdom.
Made with FlippingBook - Share PDF online